melagatran and fibrin
melagatran has been researched along with fibrin in 6 studies
Compound Research Comparison
| Studies (melagatran) | Trials (melagatran) | Recent Studies (post-2010) (melagatran) | Studies (fibrin) | Trials (fibrin) | Recent Studies (post-2010) (fibrin) |
|---|---|---|---|---|---|
| 185 | 32 | 19 | 15,994 | 328 | 3,808 |
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Eriksson, M; Larsson, A; Mattsson, C; Saldeen, T | 1 |
| Ekdahl, KN; Elgue, G; Korsgren, O; Larsson, R; Nilsson, B; Ozmen, L | 1 |
| Fenyvesi, T; Harenberg, J; Jörg, I; Piazolo, L; Zokai, K | 1 |
| Björnheden, T; Carlsson, S; Grip, L; Mattsson, C; Scherstén, F; Wahlund, G | 1 |
| Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI | 1 |
| Bylock, A; Christersson, C; Oldgren, J; Siegbahn, A; Wallentin, L | 1 |
Trials
1 trial(s) available for melagatran and fibrin
| Article | Year |
|---|---|
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Topics: Aged; Azetidines; Benzylamines; Biomarkers; Blood Coagulation; Dose-Response Relationship, Drug; Female; Fibrin; Glycine; Humans; Male; Myocardial Infarction; Partial Thromboplastin Time; Pharmacokinetics; Thrombin; Time Factors | 2005 |
Other Studies
5 other study(ies) available for melagatran and fibrin
| Article | Year |
|---|---|
Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Endotoxemia; Female; Fibrin; Glycine; Hemodynamics; Liver; Male; Platelet Count; Swine; Tumor Necrosis Factor-alpha | 2000 |
Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation.
Topics: ABO Blood-Group System; Aged; Aged, 80 and over; Anticoagulants; Azetidines; Benzylamines; Blood Platelets; Cadaver; CD11 Antigens; Female; Fibrin; Glycine; Humans; Immunohistochemistry; Inflammation; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Middle Aged; Neutrophils; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Thrombosis | 2002 |
Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
Topics: Antithrombin III; Azetidines; Benzylamines; Fibrin; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Hirudins; Humans; Models, Cardiovascular; Peptide Hydrolases; Platelet Activation; Platelet Factor 4; Thrombin; Thrombosis | 2002 |
Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model.
Topics: Angioplasty, Balloon, Coronary; Animals; Azetidines; Benzylamines; Blood Platelets; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fibrin; Fibrinolytic Agents; Glycine; Male; Models, Animal; Platelet Adhesiveness; Radioactive Tracers; Swine; Thrombosis | 2003 |
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Topics: Animals; Arteries; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Glycine; Hemorrhage; Hirudin Therapy; Hirudins; Male; Rabbits; Risk Assessment; Thrombin; Thrombosis | 2003 |